Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.

Jianping XuXiaoyan LiuSheng YangXiangru ZhangYuan-Kai Shi

Published in: Asia-Pacific journal of clinical oncology (2017)

Apatinib is effective and well tolerated in patients with advanced NSCLC, even at a dosage of 500 mg qd, and might offer a new option for the treatment of such patients with brain metastases.

Keyphrases

advanced non small cell lung cancer
brain metastases
small cell lung cancer
epidermal growth factor receptor
combination therapy
randomized controlled trial
tyrosine kinase
study protocol
smoking cessation